Localization and characterization of pituitary adenylate cyclase-activating polypeptide receptors in the human cerebellum during development

Journal of Comparative Neurology

Volumn 496, Issue 4, 2006, Pages 468-478

  Basille, Magali ^a   Cartier, Dorthe ^a   Vaudry, David ^a   Lihrmann, Isabelle ^a   Fournier, Alain ^b   Freger, Pierre ^c   Gallo Payet, Nicole ^d   Vaudry, Hubert ^a   Gonzalez, Bruno ^a  

^a UNIVERSITÉ DE ROUEN   (France)

^b INRS INSTITUT ARMAND FRAPPIER   (Canada)

^c HÔPITAL CHARLES NICOLLE   (France)

^d UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

Binding sites; Cerebellar cortex; In situ hybridization; Neuropeptides; Ontogeny; Pituitary adenylate cyclase activating polypeptide receptor 1; Vasoactive intestinal polypeptide pituitary adenylate cyclase activating polypeptide receptors 1 and 2

Indexed keywords

HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR; IODINE 125; MESSENGER RNA; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR 2;

ADULT; ARTICLE; BINDING SITE; BRAIN DEVELOPMENT; CEREBELLUM; FETUS; GRANULE CELL; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MEDULLA OBLONGATA; NEUROEPITHELIUM; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD;

ADULT; AUTORADIOGRAPHY; CEREBELLUM; CHILD; HUMANS; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE, TYPE I; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; RNA, MESSENGER; TISSUE DISTRIBUTION;

EID: 33744500262     PISSN: 00219967     EISSN: 10969861     Source Type: Journal    
DOI: 10.1002/cne.20934     Document Type: Article

References (44)

1. Adamou JE, Aiyar N, Van Horn S, Elshourbagy NA. 1995. Cloning and functional characterization of the human vasoactive intestinal peptide (VIP)-2 receptor. Biochem Biophys Res Commun 209:385-392.
2. Alexandre D, Vaudry H, Grumolato L, Turquier V, Founiier A, Jegou S, Anouar Y. 2002. Novel splice variants of type I pituitary adenylate cyclase-activating polypeptide receptor in frog exhibit altered adenylate cyclase stimulation and differential relative abundance. Endocrinology 143:2680-2692.
3. Basille M, Gonzalez BJ, Leroux P, Jeandel L, Fournier A, Vaudry H. 1993. Localization and characterization of PACAP receptors in the rat cerebellum during development: evidence for a stimulatory effect of PACAP on immature cerebellar granule cells. Neuroscience 57:329-338.
4. Basille M, Gonzalez BJ, Fournier A, Vaudry H. 1994. Ontogeny of pituitary adenylate cyclase-activating polypeptide (PACAP) receptors in the rat cerebellum: a quantitative autoradiographic study. Brain Res 82:81-89.
5. Basille M, Vaudry D, Coulouarn Y, Jegou S, Lihrmann I, Fournier A, Vaudry H, Gonzalez B. 2000. Comparative distribution of pituitary adenylate cyclase-activating polypeptide (PACAP) binding sites and PACAP receptor mRNAs in the rat brain during development. J Comp Neurol 425:495-509.
6. Cazillis M, Gonzalez BJ, Billardun C, Lombet A, Fraiehard A, Samarut J, Gressens P, Vaudry H, Rostene W. 2004. VIP and PACAP induce selective neuronal differentiation of mouse embryonic stem cells. Eur J Neurosci 19:798-808.
7. Chartrel N, Tonon MC, Vaudry H, Conlon JM. 1991. Primary structure of frog pituitary adenylate cyclase-activating polypeptide (PACAP) and effects of ovine PACAP on frog pituitary. Endocrinology 129:3367-3371.
8. Chomczynski P, Sacchi N. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-ehloroform extraction. Anal Biochem 162:156-159.
9. Di Matteo V, Esposito E. 2003. Biochemical and therapeutic effects of antioxidants in the treatment of Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Curr Drug Target CNS Neurol Disord 2:95-107.
10. Falluel-Morel A, Aubert N, Vaudry D, Basille M, Fontaine M, Fournier A, Vaudry H, Gonzalez BJ. 2004. Opposite regulation of the mitochondrial apoptotic pathway by C2-ceramide and PACAP through a MAP-kinase-dependent mechanism in cerebellar granule cells. J Neurochem 91: 1231-1243.
11. Falluel-Morel A, Vaudry D, Aubert N, Galas L, Benard M, Basille M, Fontaine M, Fournier A, Vaudry H, Gonzalez BJ. 2005. Pituitary adenylate cyclase-activating polypeptide prevents the effects of ceramides on migration, neurite outgrowth, and cytoskeleton remodeling. Proc Natl Acad Sci U S A 102:2637-2642.
12. Gonzalez BJ, Basille M, Vaudry D, Fournier A, Vaudry H. 1997. Pituitary adenylate cyclase-activating polypeptide promotes cell survival and neurite outgrowth in rat cerebellar neuroblasts. Neuroscience 78:419-430.
13. Gressens P, Arquie C, Hill JM, Marret S, Sahir N, Robberecht P, Evrard P. 2000. VIP and PACAP 38 modulate ibotenate-induced neuronal heterotopias in the newborn hamster neocortex. J Neuropathol Exp Neurol 59:1051-1062.
14. Hu Z, Lelievre V, Chao A, Zhou X, Waschek JA, 2000. Characterization and messenger ribonucleic acid distribution of a cloned pituitary adenylate cyclase-activating polypeptide type I receptor in the frog Xenopus laevis brain. Endocrinology 14:657-665.
15. Jeandel L, Yon L, Chartrel N, Gonzalez B, Fournier A, Conlon JM, Vaudry H. 1999. Characterization and localization of pituitary adenylate cyclase-activating polypeptide (PACAP) binding sites in the brain of the frog Rana ridibunda. J Comp Neurol 412:218-228.
16. Laquerriere A, Leroux P, Bodenant C, Gonzalez B, Tayot J, Vaudry H. 1994. Quantitative autoradiographic study of somatostatin receptors in the adult human cerebellum. Neuroscience 62:1147-1154.
17. Masuo Y, Ohtaki T, Masuda Y, Tsuda M, Fujino M. 1992. Binding sites for pituitary adenylate cyclase activating polypeptide (PACAP): comparison with vasoactive intestinal polypeptide (VIP) binding site localization in rat brain sections. Brain Res 575:113-123.
18. Mei YA, Vaudry D, Basille M, Castel H, Fournier A, Vaudry H, Gonzalez BJ. 2004. PACAP inhibits delayed rectifier potassium current via a cAMP/PKA transduction pathway: evidence for the involvement of Iκ in the anti-apoptotic action of PACAP. Eur J Neurosci 19:1446-1458.
19. Miyata A, Arimura A, Dahl RR, Minamino N, Uehara A, Jiang L, Culler MD, Coy DH. 1989. Isolation of a novel 38-residue hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 164:567-574.
20. Miyata A, Jiang L, Dahl RD, Kitada C, Kubo K, Fujino M, Minamino N, Arimura A. 1990. Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochem Biophys Res Commun 170:643-648.
21. Nicot A, Lelievre V, Tam J, Waschek JA, DiCicco-Bloom E. 2002. Pituitary adenylate cyclase-activating polypeptide and sonic hedgehog interact to control cerebellar granule precursor cell proliferation. J Neurosci 22:9244-9254.
22. Nielsen HS, Hannibal J, Fahrenkrug J. 1998. Expression of pituitary adenylate cyclase activating polypeptide (PACAP) in the postnatal and adult rat cerebellar cortex. Neuroreport 9:2639-2642.
23. Palkovits M, Somogyvari-Vigh A, Arimura A. 1995. Concentrations of pituitary adenylate cyclase activating polypeptide (PACAP) in human brain nuclei. Brain Res 699:116-120.
24. Pisegna JR, Wank SA. 1996. Cloning and characterization of the signal transduction of four splice variants of the human pituitary adenylate cyclase activating polypeptide receptor. Evidence for dual coupling to adenylate cyclase and phospholipase C. J Biol Chem 271:17267-17274.
25. Reglodi D, Somogyvari-Vigh A, Vigh S, Kozicz T, Arimura A. 2000. Delayed systemic administration of PACAP38 is neuroprotective in transient middle cerebral artery occlusion in the rat. Stroke 31:1411-1417.
26. Sheward WJ, Lutz EM, Copp AJ, Harmar AJ. 1998. Expression of PACAP, and PACAP type 1 (PAC1) receptor mRNA during development of the mouse embryo. Brain Res Dev Brain Res 109:245-253.
27. Spengler D, Waeber C, Pantaloni C, Holsboer F, Bockaert J, Seeburg PH, Journot L. 1993. Differential signal transduction by five splice variants of the PACAP receptor. Nature 365:170-175.
28. Sreedharan SP, Huang JX, Cheung MC, Goetzl EJ. 1995. Structure, expression, and chromosomal localization of the type I human vasoactive intestinal peptide receptor gene. Proc Natl Acad Sci U S A 92:2939-2945.
29. Streeter G. 1920. Weight, sitting height, head size, foot length and menstrual age of the human embryo. Contrib Embryol 11:143-179.
30. Suda K, Smith DM, Ghatei MA, Murphy JK, Bloom SR. 1991. Investigation and characterization of receptors for pituitary adenylate cyclase-activating polypeptide in human brain by radioligand binding and chemical cross-linking. J Clin Endocrinol Metab 72:958-964.
31. Suda K, Smith DM, Ghatei MA, Bloom SR. 1992. Investigation of the interaction of VIP binding sites with VIP and PACAP in human brain. Neurosci Lett 137:19-23.
32. Suh J, Lu N, Nicot A, Tatsuno I, DiCicco-Bloom E, 2001. PACAP is an anti-mitogenic signal in developing cerebral cortex. Nat Neurosci 4:123-124.
33. Tamas A, Reglodi D, Szanto Z, Borsiczky B, Nemeth J, Lengvari I. 2002. Comparative neuroprotective effects of preischemic PACAP and VIP administration in permanent occlusion of the middle cerebral artery in rats. Neuroendocrinol Lett 23:249-254.
34. Uchida D, Arimura A, Somogyvari-Vigh A, Shioda S, Banks WA. 1996. Prevention of ischemia-induced death of hippocampal neurons by pituitary adenylate cyclase activating polypeptide. Brain Res 736:280-286.
35. Vaudry D, Gonzalez BJ, Basille M, Anouar Y, Fournier A, Vaudry H. 1998. Pituitary adenylate cyclase-activating polypeptide stimulates both c-fos gene expression and cell survival in rat cerebellar granule neurons through activation of the protein kinase A pathway. Neuroscience 84:801-812.
36. Vaudry D, Gonzalez BJ, Basille M, Fournier A, Vaudry H. 1999. Neurotrophic activity of pituitary adenylate cyclase-activating polypeptide on rat cerebellar cortex during development. Proc Natl Acad Sci U S A 96:9415-9420.
37. Vaudry D, Gonzalez BJ, Basille M, Pamantung TF, Fontaine M, Fournier A, Vaudry H. 2000a. The neuroprotective effect of pituitary adenylate cyclase-activating polypeptide on cerebellar granule cells is mediated through inhibition of the CED3-related cysteine protease caspase-3/ CPP32. Proc Natl Acad Sci U S A 97:13390-13395.
38. Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H. 2000b. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 52:269-324.
39. Vaudry D, Pamantung TF, Basille M, Rousselle C, Fournier A, Vaudry H, Beauvillain JC, Gonzalez BJ. 2002a. PACAP protects cerebellar granule neurons against oxidative stress-induced apoptosis. Eur J Neurosci 15:1451-1460.
40. Vaudry D, Rousselle C, Basille M, Falluel-Morel A, Pamantung TF, Fontaine M, Fournier A, Vaudry H, Gonzalez BJ. 2002b. Pituitary adenylate cyclase-activating polypeptide protects rat cerebellar granule neurons against ethanol-induced apoptotic cell death. Proc Natl Acad Sci U S A 99:6398-6403.
41. Vaudry D, Falluel-Morel A, Basille M, Pamantung TF, Fontaine M, Fournier A, Vaudry H, Gonzalez BJ. 2003a. Pituitary adenylate cyclase-activating polypeptide prevents C2-ceramide-induced apoptosis of cerebellar granule cells. J Neurosci Res 72:303-316.
42. Vaudry D, Falluel-Morel A, Leuillet S, Vaudry H, Gonzalez BJ. 2003b. Regulators of cerebellar granule cell development act through specific signaling pathways. Science 300:1532-1534.
43. Vaudry D, Hamelink C, Damadzic R, Eskay R, Gonzalez BJ, Eiden LE. 2005. Endogenous PACAP acts as a stress response peptide to protect cerebellar neurons from ethanol or oxidative insult. Peptides (in press).
44. Yon L, Alexandre D, Montero M, Chartrel N, Jeandel L, Vallarino M, Conlon JM, Kikuyama S, Fournier A, Gracia-Navarro F, Roubos E, Chow B, Arimura A, Anouar Y, Vaudry H. 2001. Pituitary adenylate cyclase-activating polypeptide and its receptors in amphibians. Microsc Res Techniq 54:137-157.